Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
Myriad Genetics Inc. (MYGN) reported that Chief Technology Officer Raj Jampa received a one-time non-qualified stock option retention award covering 58,560 shares of common stock on November 6, 2026. The options have an exercise price of $5.92 per share and vest and become exercisable in full on November 6, 2029, subject to continued service through that date and the plan and award agreement. They expire November 6, 2036.
Myriad Genetics granted EVP, Commercial Vishal Sikri a one-time retention award of 53,236 non-qualified stock options on November 6, 2026. Each option has a $5.92 exercise price, equal to the common stock’s closing price on the grant date. The options vest and become exercisable in full on November 6, 2029, subject to Sikri’s continued service through that date and the plan and award agreement terms; they expire November 6, 2036. His reported direct option position after the grant was 53,236 options.
Myriad Genetics granted Chief People Officer Shereen Solaiman a one-time non-qualified stock option covering 83,049 shares of common stock as a retention award. The option has an exercise price of $5.92 per share, equal to the closing price on November 6, 2026. It vests and becomes exercisable in full on November 6, 2029, subject to continued service through that date, and expires November 6, 2036.
Myriad Genetics Inc. (MYGN) reports that Jennifer Lynne Fox, Chief Legal & Corp Strategy, received a one-time retention award of 139,267 non-qualified stock options on November 6, 2026. The options have a $5.92 per-share exercise price and vest and become exercisable in full on November 6, 2029, subject to her continued service through that date and the plan and award-agreement terms. They expire November 6, 2036.
Myriad Genetics Inc. Chief Scientific Officer Dale Muzzey received a one-time retention award of a non-qualified stock option covering 92,632 common shares. The option has a $5.92 exercise price and vests and becomes exercisable in full on November 6, 2029, subject to continued service through that date. It expires November 6, 2036.
Myriad Genetics Inc. Chief Operating Officer Mark Verratti received a one-time retention award in the form of a non-qualified stock option covering 146,933 shares of common stock on November 6, 2026. The option has a $5.92 per-share exercise price, equal to the common stock’s closing price on the grant date, and expires November 6, 2036. It vests and becomes exercisable in full on November 6, 2029, subject to his continued service through that date and the plan and award agreement terms.
Myriad Genetics (MYGN) Chief Financial Officer Benjamin Richard Wheeler received a one-time non-qualified stock option grant on November 6, 2026, as a retention award. The option covers 121,379 shares of common stock and has a $5.92 exercise price, equal to the common stock’s closing price on the grant date. It vests and becomes exercisable in full on November 6, 2029, subject to his continued service through that date, and expires on November 6, 2036.
Myriad Genetics, Inc. (MYGN) approved one-time retention stock option awards on November 6, 2026, for named executive officers Benjamin R. Wheeler, Chief Financial Officer (121,379 shares), Mark S. Verratti, Chief Operating Officer (146,933 shares), and Dale Muzzey, Chief Scientific Officer (92,632 shares). The company said the awards are intended to promote leadership retention and continuity as it pursues initiatives to improve operational efficiencies and financial performance.
Each award vests and becomes exercisable on the third anniversary of its grant date, subject to the recipient’s continued service and the terms of the 2026 Plan and related stock option agreement. Each has a 10-year term, subject to earlier termination under those terms.
Myriad Genetics reported third-quarter 2026 revenue of $202.7 million, compared with $205.7 million a year earlier, and a net loss of $43.9 million, versus $27.4 million. Cancer Care Continuum revenue was $123.9 million, Mental Health revenue was $39.5 million and Prenatal Health revenue was $39.3 million. For the first nine months, revenue was $593.8 million, compared with $614.7 million, and net loss was $121.2 million, compared with $358.0 million. The prior-year nine-month period included $316.7 million in goodwill and long-lived asset impairment charges.
Operating cash used in the first nine months was $30.5 million, versus $8.8 million a year earlier. Cash and cash equivalents were $107.1 million and long-term debt, net, was $121.1 million as of September 30, 2026. Myriad reported compliance with applicable Credit Agreement covenants as of that date.
On October 19, 2026, Myriad agreed to sell certain Prenatal Health assets and liabilities to Laboratory Corporation of America for $210 million in cash plus the value of related inventory at closing. The transaction is subject to customary closing conditions, including regulatory approvals, and was expected to close by early 2027. Myriad intends to use net proceeds for general corporate purposes, potentially including debt repayment, funding operations and investment in Cancer Care Continuum.
Myriad Genetics, Inc. detected unauthorized access within its information technology network environment on November 2, 2026. The company promptly began incident response procedures to contain the activity, investigate its scope and take remedial steps. Those steps included temporarily suspending testing operations and order management systems and resetting certain system credentials. Myriad engaged external experts to assist. Most systems have returned to normal operations, while the company continues assessing the incident, including whether patient records on systems containing patient information were accessed. As of the report, Myriad said it did not believe the incident would have a material adverse effect on its business.